Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
San Diego-based biotech firm Cidara Therapeutics has launched with $32 million in its first round of financing, which was backed by 5AM Ventures, Aisling Capital, Frazier Healthcare, and InterWest Partners. Previously known as K2 Therapeutics, the biotech was started to develop small-molecule immunotherapies that can address fungal infections in patients with compromised immune systems. Cidara’s leadership includes several former executives from Trius Therapeutics, an antibiotics firm bought last year by Cubist Pharmaceuticals.
This article has been sent to the following recipient: